JP2018512153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512153A5 JP2018512153A5 JP2017553223A JP2017553223A JP2018512153A5 JP 2018512153 A5 JP2018512153 A5 JP 2018512153A5 JP 2017553223 A JP2017553223 A JP 2017553223A JP 2017553223 A JP2017553223 A JP 2017553223A JP 2018512153 A5 JP2018512153 A5 JP 2018512153A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- lymphoma
- seq
- bcma
- specific car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 37
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 37
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 14
- 210000002865 immune cell Anatomy 0.000 claims 14
- 230000004068 intracellular signaling Effects 0.000 claims 14
- 208000003950 B-cell lymphoma Diseases 0.000 claims 11
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000003211 malignant effect Effects 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 108020001756 ligand binding domains Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229940127073 nucleoside analogue Drugs 0.000 claims 4
- 102000009438 IgE Receptors Human genes 0.000 claims 3
- 108010073816 IgE Receptors Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 206010010144 Completed suicide Diseases 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 108010033174 Deoxycytidine kinase Proteins 0.000 claims 2
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 2
- 229960000928 clofarabine Drugs 0.000 claims 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical group C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001541 thymus gland Anatomy 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000003701 histiocyte Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021122349A JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146825P | 2015-04-13 | 2015-04-13 | |
| US62/146,825 | 2015-04-13 | ||
| US201662286473P | 2016-01-25 | 2016-01-25 | |
| US62/286,473 | 2016-01-25 | ||
| US201662301177P | 2016-02-29 | 2016-02-29 | |
| US62/301,177 | 2016-02-29 | ||
| PCT/IB2016/051808 WO2016166630A1 (en) | 2015-04-13 | 2016-03-30 | Chimeric antigen receptors targeting b-cell maturation antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021122349A Division JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512153A JP2018512153A (ja) | 2018-05-17 |
| JP2018512153A5 true JP2018512153A5 (enExample) | 2019-05-09 |
| JP6921001B2 JP6921001B2 (ja) | 2021-08-18 |
Family
ID=55650627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553223A Active JP6921001B2 (ja) | 2015-04-13 | 2016-03-30 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
| JP2021122349A Active JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021122349A Active JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294304B2 (enExample) |
| EP (2) | EP3283520B1 (enExample) |
| JP (2) | JP6921001B2 (enExample) |
| KR (3) | KR102208443B1 (enExample) |
| CN (2) | CN114149511A (enExample) |
| AU (3) | AU2016248947B2 (enExample) |
| CA (1) | CA2925589A1 (enExample) |
| CO (1) | CO2017010502A2 (enExample) |
| DK (1) | DK3283520T3 (enExample) |
| ES (2) | ES2807591T3 (enExample) |
| IL (2) | IL297223B2 (enExample) |
| MX (2) | MX377809B (enExample) |
| MY (1) | MY188432A (enExample) |
| PE (1) | PE20171653A1 (enExample) |
| PH (1) | PH12017501728A1 (enExample) |
| RU (1) | RU2706582C2 (enExample) |
| SG (2) | SG11201707089WA (enExample) |
| TW (2) | TWI631138B (enExample) |
| WO (1) | WO2016166630A1 (enExample) |
| ZA (1) | ZA201706384B (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6698546B2 (ja) * | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| CN107406516B (zh) | 2015-01-26 | 2021-11-23 | 塞勒克提斯公司 | 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR) |
| CN119708245A (zh) | 2015-04-13 | 2025-03-28 | 辉瑞公司 | 治疗性抗体和它们的用途 |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| PE20200400A1 (es) | 2016-04-01 | 2020-02-26 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| SG10201912489QA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| SG11201808797XA (en) | 2016-04-08 | 2018-11-29 | Immunocore Ltd | T cell receptors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11219646B2 (en) * | 2016-09-30 | 2022-01-11 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| KR20250072712A (ko) | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| JP7350313B2 (ja) * | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| TWI757499B (zh) | 2017-06-02 | 2022-03-11 | 美商輝瑞大藥廠 | 對flt3具特異性之抗體及其用途 |
| PE20241587A1 (es) | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| DK3703750T3 (da) | 2017-11-01 | 2025-02-10 | Juno Therapeutics Inc | Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| KR20200099137A (ko) | 2017-11-06 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 감마 세크레타제 억제제의 조합 |
| CN111787938A (zh) | 2017-11-15 | 2020-10-16 | 诺华股份有限公司 | 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法 |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| AU2019214163B2 (en) * | 2018-02-01 | 2021-06-24 | Innovent Biologics (Suzhou) Co., Ltd. | Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof |
| EP3674327A4 (en) * | 2018-02-01 | 2021-05-05 | Nanjing Iaso Biotherapeutics Co., Ltd. | CHEMICAL ANTIGENIC RECEPTOR (CAR) BINDING TO BCMA AND ITS APPLICATIONS |
| PE20211299A1 (es) * | 2018-02-01 | 2021-07-20 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70 |
| TWI878213B (zh) | 2018-02-01 | 2025-04-01 | 美商輝瑞大藥廠 | 對cd70具特異性抗體及其用途 |
| US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| SG11202007495SA (en) | 2018-02-21 | 2020-09-29 | Celgene Corp | Bcma-binding antibodies and uses thereof |
| JP7526101B2 (ja) | 2018-03-02 | 2024-07-31 | アロジーン セラピューティクス，インコーポレイテッド | 誘導性キメラサイトカイン受容体 |
| IT201800003464A1 (it) | 2018-03-13 | 2019-09-13 | Ospedale Pediatrico Bambino Gesu | Cellule T CAR-CD30 per il trattamento di tumori CD30+ |
| CN116514995A (zh) * | 2018-04-12 | 2023-08-01 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN112384531B (zh) | 2018-06-01 | 2024-05-14 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| MY208825A (en) | 2018-06-13 | 2025-05-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| DK4324851T3 (da) * | 2018-07-19 | 2025-10-06 | Regeneron Pharma | Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3107515A1 (en) * | 2018-07-24 | 2020-01-30 | Carsgen Therapeutics Co., Ltd. | Method for tumor treatment with immune effector cells |
| CN110850067B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 嵌合抗原受体亲和力检测方法 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| DK3844267T3 (da) | 2018-08-31 | 2025-09-22 | Novartis Ag | Fremgangsmåder til fremstilling af kimære antigenreceptorudtrykkende celler |
| KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
| JP7742773B2 (ja) | 2018-11-01 | 2025-09-22 | ジュノー セラピューティクス インコーポレイテッド | Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体 |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| BR112021010279A2 (pt) * | 2018-12-01 | 2021-08-24 | Allogene Therapeutics, Inc. | Receptores de antígeno quimérico que alvejam antígeno de maturação de células b e métodos de uso dos mesmos |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| MY206523A (en) | 2019-03-01 | 2024-12-19 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| US20230174627A1 (en) * | 2019-05-14 | 2023-06-08 | Jeffrey W. FROUDE | Antibodies to sudan and ebola virus |
| WO2020236964A1 (en) * | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered expression of cell surface and secreted sialidase by car t cells for increased efficacy in solid tumors |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| JP7677908B2 (ja) * | 2019-05-30 | 2025-05-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| WO2021026362A1 (en) | 2019-08-07 | 2021-02-11 | Edifice Health, Inc. | Treatment of prevention of cardiovascular disease |
| JP2022544592A (ja) | 2019-08-16 | 2022-10-19 | ヤンセン バイオテツク，インコーポレーテツド | 改善された機能を有する治療用免疫細胞及びその作製方法 |
| JP2022548902A (ja) * | 2019-09-18 | 2022-11-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
| JP2023501871A (ja) * | 2019-09-20 | 2023-01-20 | 上海吉倍生物技術有限公司 | Ｂｃｍａ標的化抗体及びキメラ抗原受容体 |
| BR112022006364A2 (pt) * | 2019-10-01 | 2022-06-28 | Epsilogen Ltd | Anticorpo híbrido |
| CA3159541A1 (en) * | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| AU2020393912B2 (en) | 2019-11-26 | 2025-11-20 | Novartis Ag | Chimeric antigen receptors binding BCMA and CD19 and uses thereof |
| TW202140533A (zh) * | 2020-01-16 | 2021-11-01 | 美商異基因治療有限公司 | 靶向B 細胞成熟抗原之嵌合抗原受體及γ 分泌酵素抑制劑之組合療法 |
| IL295470A (en) | 2020-02-24 | 2022-10-01 | Allogene Therapeutics Inc | Bcma car-t cells with enhanced activities |
| CN115175695A (zh) | 2020-02-27 | 2022-10-11 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| JP7781761B2 (ja) | 2020-02-27 | 2025-12-08 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| GB202005216D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US20210315921A1 (en) * | 2020-04-13 | 2021-10-14 | Edifice Health, Inc. | Compounds and Methods for Modifying iAge |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| KR102316091B1 (ko) * | 2020-06-17 | 2021-10-25 | 국립암센터 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| EP4199960A2 (en) | 2020-08-21 | 2023-06-28 | Novartis AG | Compositions and methods for in vivo generation of car expressing cells |
| CN114106176B (zh) * | 2020-09-01 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
| USD939199S1 (en) | 2021-01-29 | 2021-12-28 | O2 Partners, Llc | Shoe insole |
| JP2024515793A (ja) | 2021-04-27 | 2024-04-10 | ノバルティス アーゲー | ウイルスベクター生産システム |
| AR126838A1 (es) | 2021-08-20 | 2023-11-22 | Novartis Ag | Métodos para preparar células que expresan receptores de antígeno quiméricos |
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| EP4515231A1 (en) | 2022-04-28 | 2025-03-05 | Allogene Therapeutics, Inc. | Methods for donor cell analysis |
| US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| CN119836438A (zh) * | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | B-细胞成熟抗原（bcma）抗独特型抗体 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ATE360693T1 (de) | 1999-08-17 | 2007-05-15 | Biogen Idec Inc | Baff rezeptor (bcma), ein immunoregulatorisches mittel |
| WO2001062895A2 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2438682A1 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| US20080267965A1 (en) | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
| TWI464178B (zh) * | 2007-03-22 | 2014-12-11 | Genentech Inc | 細胞凋亡抗-ｉｇｅ抗體 |
| MX2011009430A (es) | 2009-03-10 | 2011-11-18 | Biogen Idec Inc | Anticuerpos anti-bcma. |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| CA2815512A1 (en) | 2010-10-27 | 2012-05-03 | Philippe Duchateau | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| BR112013028779B8 (pt) * | 2011-05-27 | 2021-04-20 | Glaxo Group Ltd | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RU2650805C2 (ru) * | 2012-04-11 | 2018-04-17 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| CA2870545A1 (en) | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Cd3 binding polypeptides |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| RU2663725C2 (ru) | 2012-09-04 | 2018-08-08 | Селлектис | Многоцепочечный химерный антигенный рецептор и его применения |
| EP2914628A1 (en) * | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体 |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HK1220205A1 (zh) * | 2013-03-15 | 2017-04-28 | Celgene Corporation | 修饰的t淋巴细胞 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| CN105452287A (zh) * | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
| MX374681B (es) | 2013-05-13 | 2025-03-06 | Cellectis | Receptor quimérico de antígeno específico para cd19 y sus usos. |
| CN105378067A (zh) | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015221933B2 (en) | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| JP6698546B2 (ja) * | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| SG11201608415QA (en) | 2014-04-30 | 2016-11-29 | Max Delbrück Ct Für Molekulare Medizin In Der Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| SG10202013144UA (en) | 2014-12-12 | 2021-02-25 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| CN107406516B (zh) | 2015-01-26 | 2021-11-23 | 塞勒克提斯公司 | 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR) |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| CN119708245A (zh) | 2015-04-13 | 2025-03-28 | 辉瑞公司 | 治疗性抗体和它们的用途 |
| BR112021010279A2 (pt) * | 2018-12-01 | 2021-08-24 | Allogene Therapeutics, Inc. | Receptores de antígeno quimérico que alvejam antígeno de maturação de células b e métodos de uso dos mesmos |
-
2016
- 2016-03-30 SG SG11201707089WA patent/SG11201707089WA/en unknown
- 2016-03-30 MX MX2017013298A patent/MX377809B/es unknown
- 2016-03-30 ES ES16714020T patent/ES2807591T3/es active Active
- 2016-03-30 CA CA2925589A patent/CA2925589A1/en active Pending
- 2016-03-30 EP EP16714020.1A patent/EP3283520B1/en active Active
- 2016-03-30 PE PE2017001979A patent/PE20171653A1/es unknown
- 2016-03-30 CN CN202111463749.6A patent/CN114149511A/zh active Pending
- 2016-03-30 WO PCT/IB2016/051808 patent/WO2016166630A1/en not_active Ceased
- 2016-03-30 KR KR1020177032318A patent/KR102208443B1/ko active Active
- 2016-03-30 RU RU2017133952A patent/RU2706582C2/ru active
- 2016-03-30 CN CN201680021803.2A patent/CN107980046B/zh active Active
- 2016-03-30 SG SG10201912666PA patent/SG10201912666PA/en unknown
- 2016-03-30 TW TW105110156A patent/TWI631138B/zh active
- 2016-03-30 US US15/085,317 patent/US10294304B2/en active Active
- 2016-03-30 MY MYPI2017703826A patent/MY188432A/en unknown
- 2016-03-30 ES ES20172811T patent/ES3039918T3/es active Active
- 2016-03-30 JP JP2017553223A patent/JP6921001B2/ja active Active
- 2016-03-30 KR KR1020227000405A patent/KR102528825B1/ko active Active
- 2016-03-30 TW TW107117083A patent/TWI700298B/zh active
- 2016-03-30 IL IL297223A patent/IL297223B2/en unknown
- 2016-03-30 DK DK16714020.1T patent/DK3283520T3/da active
- 2016-03-30 AU AU2016248947A patent/AU2016248947B2/en active Active
- 2016-03-30 KR KR1020217002139A patent/KR102349475B1/ko active Active
- 2016-03-30 EP EP20172811.0A patent/EP3757128B1/en active Active
-
2017
- 2017-09-03 IL IL254276A patent/IL254276B2/en unknown
- 2017-09-20 PH PH12017501728A patent/PH12017501728A1/en unknown
- 2017-09-21 ZA ZA2017/06384A patent/ZA201706384B/en unknown
- 2017-10-13 MX MX2020012573A patent/MX2020012573A/es unknown
- 2017-10-13 CO CONC2017/0010502A patent/CO2017010502A2/es unknown
-
2019
- 2019-04-15 US US16/384,719 patent/US11312782B2/en active Active
-
2020
- 2020-10-14 AU AU2020256365A patent/AU2020256365B2/en active Active
-
2021
- 2021-07-27 JP JP2021122349A patent/JP7301915B2/ja active Active
-
2022
- 2022-03-15 US US17/695,769 patent/US11912776B2/en active Active
-
2023
- 2023-08-24 AU AU2023219928A patent/AU2023219928A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512153A5 (enExample) | ||
| JP7212222B2 (ja) | Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用 | |
| CA2784814C (en) | Heterodimer binding proteins and uses thereof | |
| RU2017133952A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток | |
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| WO2020247843A2 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| CN110325209A (zh) | 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途 | |
| JP2016513467A5 (enExample) | ||
| KR20230100748A (ko) | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 | |
| JP2015527070A5 (enExample) | ||
| JP2019517539A (ja) | 併用療法 | |
| JP2016514462A5 (enExample) | ||
| CN113614109A (zh) | 双功能抗pd-1/il-7分子 | |
| EP3774921A1 (en) | Antibody variable domains targeting dll3, and use thereof | |
| JP2017522893A5 (enExample) | ||
| US20220411512A1 (en) | Combination treatment for cancer | |
| JP2023524997A (ja) | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 | |
| WO2021223720A1 (zh) | 人源化cd19抗体及其应用 | |
| TW202313682A (zh) | 抗icos抗體之用途 | |
| CA3070290A1 (en) | Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody | |
| CN114585416A (zh) | 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 | |
| CN114790241B (zh) | 抗tigit抗体及其应用 | |
| CN114729305A (zh) | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 | |
| CN110709423A (zh) | 用icos激动剂和ox40激动剂治疗癌症的组合疗法 | |
| WO2024173376A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies |